Biotech Adam Feuerstein STAT Plus: Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies
Biotech Adam Feuerstein STAT Plus: Mirati study results set new response bar for KRAS-blocking lung cancer drugs
